Patients with soft tissue damage will experience dramatic improvements with LifeSprout Tissue Regenerative Matrix (TRM). Hai-Quan Mao (Professor, MSE/INBT ChemBE), collaborating with Johns Hopkins School of Medicine faculty specialists Justin Sacks and Sashank Reddy, developed the technology that combines a tissue-plumping hydrogel with a cell-supporting nanofiber framework. Resulting tissue repairs are individualized and have a reduced chance of scarring, as well as being scar and inflammation free. The Louis B. Thalheimer Funds grant, among other funds, will help move LifeSprout TRM from prototype to pre-clinical testing and FDA approval.
Often it takes years to bring a new technology through the approval process from bench top to bedside. However, because this technology uses materials that have been previously approved by the FDA, the time to clinical use should be shortened.
Watch this video by Johns Hopkins video storyteller Renee Fischer on LifeSprout Tissue Regenerative Matrix. Read more about the technology here on the Rising To the Challenge website.